1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

Setback Follows Camzyos Stumble In nHCM

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Prescribers already treat schizophrenia with combination therapy without approved adjunctive medicines (Shutterstock)
Key Takeaways
  • Bristol’s Cobenfy did not achieve statistical significance on the primary endpoint in the Phase III ARISE clinical trial testing the drug as an add-on to antipsychotic medicines in schizophrenia.

Bristol Myers Squibb made a $14bn gamble when it agreed to buy Karuna Therapeutics in late 2023 for its drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Scrip